Publication: Topiramate induced bilateral angle-closure glaucoma
| creativeworkseries.issn | 1812-2027 | |
| dc.contributor.author | Singh, SK | |
| dc.contributor.author | Thapa, SS | |
| dc.contributor.author | Badhu, BP | |
| dc.date.accessioned | 2025-07-27T07:01:11Z | |
| dc.date.available | 2025-07-27T07:01:11Z | |
| dc.date.issued | 2007 | |
| dc.description | Singh SK, Thapa SS, Badhu BP 1Medical Director, Mechi Eye Care Centre, Birtamod, Jhapa, Nepal, 2 Glaucoma Consultant, Tilganga Eye Centre, Kathmandu, Nepal, Additional Professor, Eye department, B.P.K. Institute of Health Sciences, Dharan | |
| dc.description.abstract | Topiramate is a sulfamate-substituted monosaccharide and is used as an antiepileptic medication 1. It can also be used as a prophylactic agent for headache from migraine2 . The main purpose of this article is to create awareness among medical colleagues regarding severe ophthalmic side effect of topiramate. This is the first reported case of topiramate induced bilateral angle-closure glaucoma in Nepal. This case was managed successfully by discontinuing topiramate and by starting anti-glaucoma medication along with atropine eye drops which were tapered and eventually discontinued. | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14572/734 | |
| dc.language.iso | en_US | |
| dc.publisher | Kathmandu University | |
| dc.title | Topiramate induced bilateral angle-closure glaucoma | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.article.type | Case Report | |
| oaire.citation.endPage | 236 | |
| oaire.citation.startPage | 234 | |
| relation.isJournalIssueOfPublication | 20924142-b1f6-494d-ac74-a8f01ad5fadf | |
| relation.isJournalIssueOfPublication.latestForDiscovery | 20924142-b1f6-494d-ac74-a8f01ad5fadf | |
| relation.isJournalOfPublication | a782b7ff-cf89-4178-ad1c-11ed89cfe1bd |